Eliza Act Biotechnologies LLC

Akonni Biosystems, based in Frederick, MD, is a leading molecular diagnostics company specializing in the development and manufacturing of integrated molecular diagnostic instruments and consumables. Their innovative products, such as the TruTip nucleic acid purification kits and TruDiagnosis IVD systems, offer flexible solutions for a wide range of laboratory needs. With a strong focus on technology and research, Akonni holds over 40 issued patents covering various aspects of their core technologies, including specimen homogenization, nucleic acid purification, and 3D gel drop microarrays. Recognized for their groundbreaking work, Akonni Biosystems continues to revolutionize the molecular testing market with game-changing solutions for rapid and accurate disease detection.Generated from the website

Sequella Inc. is a clinical-stage pharmaceutical company based in Rockville, MD, focused on developing innovative antibiotics to combat drug-resistant bacterial, fungal, and parasitic infections. Their product pipeline addresses significant global health threats, particularly tuberculosis and its multidrug-resistant forms, which impact billions of people worldwide. With two drug candidates having completed phase 2 clinical trials and additional candidates in preclinical development, Sequella aims to tackle various infectious diseases, including Helicobacter pylori infections and Clostridium difficile. Their research also explores treatments for non-tuberculous mycobacterial infections and parasitic diseases, demonstrating a commitment to addressing critical health challenges globally. Generated from the website

Kolon TissueGene, based in Rockville, MD, is a biopharmaceutical company focused on developing advanced cell therapies aimed at treating orthopedic diseases and degenerative disorders, with a notable emphasis on osteoarthritis of the knee. Their key product, TG-C, is designed to alleviate pain, enhance function, and slow disease progression through allogeneic cell and gene therapy. With a commitment to addressing unmet medical needs, Kolon TissueGene leverages innovative technology to advance clinical-stage therapies. The company aims to reshape treatment approaches within the orthopedic field through its state-of-the-art research and development initiatives. Generated from the website